Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | MC5R | P33032 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8993155 | 1.00 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL8708196 | 1.00 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL5741392 | 0.98 | MAOA (0.54) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL17527067 | 0.96 | MAOA (0.52) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL16390835 | 0.96 | MAOA (0.52) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL3666097 | 0.96 | MAOA (0.52) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL17508108 | 0.94 | MAOA (0.54) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL8027241 | 0.92 | HDAC3 (0.50) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL17527074 | 0.92 | MAOA (0.52) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL1685452 | 0.92 | CARM1 (0.53) | HDAC3HDAC1HDAC2HDAC8NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1026150-B1 | (2-oxy substituted)-phenylalkanamide derivative, hair growth promoter and external composition for skin using the same | SHISEIDO CO LTD (JP) | 2011-06-29 | — | — | EP | disclosed |
| US-6573297-B2 | Applying an effective amount of (2-substituted oxyphenyl)alkanamide derivatives to the skin of a mammal for promoting hair growth | SHISEIDO CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| US-20020052498-A1 | (2-substituted oxyphenyl)alkanamide derivative, hair growth promoter and external composition for skin using the same | SHISEIDO CO., LTD. (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6339154-B1 | THERAPY OF HAIR LOSS IN MAMMALS AND, IN PARTICULAR, IN HUMAN | SHISEIDO CO, LTD. (JP) | 2002-01-15 | — | — | US | disclosed |
| CN-1271724-A | (2-substituted oxyphenyl) alkane acylamide derivative and hair nourishing agent, skin external use agent | SHISEIDO CO LTD (JP) | 2000-11-01 | — | — | CN | disclosed |
| EP-1026150-A1 | (2-oxy substituted)-phenylalkanamide derivative, hair growth promoter and external composition for skin using the same | SHISEIDO COMPANY LIMITED (JP) | 2000-08-09 | — | — | EP | disclosed |
| US-5677350-A | Inhibition of cancer cell growth, proliferation, and metastasis using N,N'-dα,ω-diaminoalkanes | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-10-14 | — | — | US | disclosed |
| WO-1996040096-A1 | INHIBITION OF CANCER CELL GROWTH, PROLIFERATION AND METASTASIS USING N,N'-DIBENZYL-α,φ-DIAMINOALKANES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052498-A1 | (2-substituted oxyphenyl)alkanamide derivative, hair growth promoter and external composition for skin using the same | NR2E1, NCOR2, DECR2 | HDAC3 76/4885HDAC1 154/4885HDAC2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.